AAAAAA

   
Results: 1-6 |
Results: 6
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluourouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer - A prospective randomized study (vol 22, pg 593, 1999)
Authors: Cocconi, G Bisagni, G Bella, M Aato, L Anastasi, P Carpi, A Di Costanzo, F Frassoldati, A Mosconi, A Borrini, A Buzzi, P
Citation: G. Cocconi et al., Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluourouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer - A prospective randomized study (vol 22, pg 593, 1999), AM J CL ONC, 23(2), 2000, pp. CP3-CP3
Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group forclinical research (GOIRC)
Authors: Boni, C Bisagni, G Savoldi, L Moretti, G Rondini, E Sassi, M Zadro, A De Pas, T Franciosi, V Pazzola, A Vignoli, R Banzi, MC Pajetta, V
Citation: C. Boni et al., Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group forclinical research (GOIRC), INT J CANC, 87(5), 2000, pp. 724-727
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer - A prospective randomized study
Authors: Cocconi, G Bisagni, G Bella, M Acito, L Anastasi, P Carpi, A Di Costanzo, F Frassoldati, A Mosconi, A Borrini, A Buzzi, P
Citation: G. Cocconi et al., Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer - A prospective randomized study, AM J CL ONC, 22(6), 1999, pp. 593-600
Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial
Authors: Cocconi, G Bisagni, G Ceci, G Blasio, BD De Lisi, V Passalacqua, R Zadro, A Boni, C Morandi, P Savoldi, L
Citation: G. Cocconi et al., Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial, BREAST CANC, 56(2), 1999, pp. 125-132
Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): A phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC)
Authors: Boni, C Savoldi, L Bisagni, G Ceci, G Crino, L De Lisi, V Di Costanzo, F Lasagni, L Manenti, AL Moretti, G Rondini, E Sassi, M Zadro, A
Citation: C. Boni et al., Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): A phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC), EUR J CANC, 34(12), 1998, pp. 1974-1976
Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: A phase II study
Authors: Bisagni, G Boni, C Manenti, AL Moretti, G Rondini, E Sassi, M Zadro, A Savoldi, L
Citation: G. Bisagni et al., Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: A phase II study, TUMORI, 84(6), 1998, pp. 659-661
Risultati: 1-6 |